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Abstract 
Purpose: Despite new developments in cancer therapy, chemotherapy and radiotherapy remain the cornerstone of 
breast cancer treatment. Therefore, finding ways to reduce the toxicity and increase sensitivity is particularly impor‑
tant. Tumor necrosis factor alpha (TNF‑α) exerts multiple functions in cell proliferation, differentiation and apoptosis. 
In the present study, we investigated whether TNF‑α could enhance the effect of chemotherapy and radiotherapy 
against breast cancer cells.
Methods: Cell growth was determined by MTT assay in vitro, and by using nude mouse tumor xenograft model 
in vivo. Cell cycle and apoptosis/necrosis were evaluated by flow cytometry. DNA damage was visualized by phos‑
pho‑Histone H2A.X staining. mRNA expression was assessed by using real‑time PCR. Protein expression was tested by 
Western blot assay.
Results: TNF‑α strengthened the cytotoxicity of docetaxel, 5‑FU and cisplatin against breast cancer cells both in vitro 
and in vivo. TNF‑α activated NF‑κB pathway and dependently up‑regulated expressions of CyclinD1, CyclinD2, CyclinE, 
CDK2, CDK4 and CDK6, the key regulators participating in G1→S phase transition. As a result, TNF‑α drove cells out 
of quiescent G0/G1 phase, entering vulnerable proliferating phases. Treatment of TNF‑α brought more DNA dam‑
age after Cs137‑irradiation and strengthened G2/M and S phase cell cycle arrest induced by docetaxel and cisplatin 
respectively. Moreover, the up‑regulation of RIP3 (a necroptosis marker) by 5‑FU, and the activation of RIP3 by TNF‑α, 
synergistically triggered necroptosis (programmed necrosis). Knockdown of RIP3 attenuated the synergetic effect of 
TNF‑α and 5‑FU.
Conclusion: TNF‑α presented radiotherapy‑ and chemotherapy‑sensitizing effects against breast cancer cells.
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Background
Breast cancer  is by far the most frequent cancer among 
women worldwide and accounts for 30% of all new 
cancer cases in females with a greater incidence in 
women over the age of 60 years [1–5]. Although a vari-
ety of treatments including surgical resection, adjuvant 
chemotherapy, hormonal therapy, and radiotherapy have 
been shown to improve survival and reduce the risk of 
tumor reoccurrence, breast cancer remains as one of the 
leading causes of death in women [1–5]. Chemotherapy, 
as a conventional method of cancer treatment, is gener-
ally performed by using cytotoxic agents. Radiotherapy 
plays a vital role in local treatment of lymph node metas-
tasis in breast cancer. However, chemotherapy and radi-
otherapy have effects on both normal and tumor cells, 
which means patient have to suffer side effects that come 
along, and the toxicity is always dose dependent [1, 5]. 
Therefore, finding ways to reduce the dose of chemother-
apy and radiotherapy, without affecting their therapeutic 
efficiency, is particularly important to tumor therapy.
Open Access
Cancer Cell International
*Correspondence:  kaichen@suda.edu.cn; shenmeng@suda.edu.cn; 
liwei10@suda.edu.cn 
†Xiao Wu, Meng‑Yao Wu and Min Jiang authors contributed equally to 
this work 
1 Department of Oncology, The First Affiliated Hospital of Soochow 
University, Suzhou 215006, China
Full list of author information is available at the end of the article
Page 2 of 12Wu et al. Cancer Cell Int  (2017) 17:13 
Tumor necrosis factor alpha (TNF-α) is a classical 
member of a ligand family of cytokines that include TNF, 
lymphotoxin-α (LTα), Fas ligand (FasL), CD40 ligand 
(CD40L), and TNF-related apoptosis-inducing ligand 
(TRAIL) [6]. TNF-α is a pleiotropic pro-inflammatory 
cytokine inducing a broad range of cellular responses, 
ranging from inflammatory cytokine production, cell sur-
vival, cell proliferation, cell differentiation and cell death. 
TNF-α can trigger different forms of PCD (programmed 
cell death) that are morphologically distinguished as 
apoptosis and necroptosis [7]. Lots of studies have con-
firmed that TNF-α can recruit a variety of signaling mol-
ecules to induce apoptosis and necroptosis to exert its 
cytotoxicity through binding to TNF-α receptors, includ-
ing TNF receptor-associated death domain (TRADD), 
TNF receptor-associated factor 2 (TRAF2), and receptor-
interacting protein kinase 1 and 3 (RIP1 and RIP 3) [8]. 
Therefore, TNF-α has been used as an antitumor agent 
previously because of its broad spectrums of cytotoxic 
effects against a variety of cancer cells, including colo-
rectal  cancer, melanoma and sarcoma [9–11]. However, 
the clinical application of TNF-α has been limited, largely 
due to its induction of pro-inflammatory and anti-apop-
totic gene transcription mainly via activating the NF-κB 
signal pathway, which leads to systemic toxicity. Recently, 
studies have shown that combination with low-dose 
TNF-α could enhance therapeutic effects of chemothera-
peutic drugs [12, 13].
In our present study, we investigate whether TNF-α 
could enhance the cytotoxicity of chemotherapeutics and 
radiotherapy against breast cancer cells. The mechanisms 




Human breast cancer cell lines MDA-MB-231 and 
MCF-7 were purchased from American Type Culture 
Collection (ATCC, VA, USA). Cells were maintained in 
RPMI-1640 medium (Gibco, NY, USA), supplemented 
with 10% fetal calf serum (Gibco), 100 units/ml penicil-
lin, and 100 mg/ml streptomycin. The cultures were incu-
bated at 37 °C in a humidified atmosphere with 5% CO2. 
Cells were passaged every 2–3 days to obtain exponential 
growth.
Reagents
TNF-α was purchased from Sigma (St Louis, Mis-
souri, USA). Docetaxel was purchased from Jiang Su 
Heng Rui Medicine CO., LTD. (Liangyungang, Jiangsu, 
China). 5-Flurouracil (5-FU) was purchased from Shang-
hai Xudong Haipu Pharmaceutical CO., LTD. (Shang-
hai, China). Cisplatin was purchased from Nanjing 
Pharmaceutical Factory CO., LTD. (Nanjing, Jiangsu, 
China). Bay11-7082 was purchased from Sigma (St. 
Louis, MO, USA).
MTT assay
Cellular growth was evaluated by MTT (methyl thiazolyl 
tetrazolium) assay [14]. Cells were seeded into 24-well 
tissue culture plates at 5 × 104 cells per well. After treat-
ment, MTT (Sigma) was added to each well to a final 
concentration of 0.5  mg/ml, followed by incubation at 
37 °C for 4 h. The medium was then removed, and 800 μl 
of dimethyl sulfoxide (DMSO) was added per well. The 
absorbance in each well was measured at 490 nm using 
a microplate ELISA reader (Bio-Rad Laboratories, CA, 
USA). The relative cell viability was calculated as follows: 
relative cell viability =  (mean experimental absorbance/
mean control absorbance)  ×100%. The concentration 
that caused 50% growth inhibition (IC50) was calculated 
by the modified Kärbers method [14] according to the 
formula: IC50 =  lg−1  [Xk −  i (∑p −  0.5)], in which Xk 
represents the logarithm of the highest drug concentra-
tion; i is that of ratio of adjacent concentration; and ΣP is 
the sum of the percentage of growth inhibition at various 
concentrations.
Nude mouse tumor xenograft model and treatment
Four-week-old female BALB/c athymic nude mice were 
purchased from Shanghai SLAC Laboratory Animal Co. 
Ltd (Shanghai, China) and received humane care accord-
ing to the Soochow University Institutional Animal Care 
and Treatment Committee. MDA-MB-231 cells were 
injected into the left flanks of the mice in a total volume 
of 100 μl (0.5 × 107 cells). TNF-α (20 ng each injection, 
intratumorally) [15], cisplatin (2 mg/kg per body weight, 
intraperitoneally) [16], and docetaxel (2 mg/kg per body 
weight, intravenously) [17] were administered every three 
days. 5-FU was administered intraperitoneally (10 mg/kg 
per body weight) everyday. Treatments were conducted 
for 20 days.
Cell cycle analysis
Cell cycle analysis using propidium iodide (PI, Sigma) 
was performed as previously described [14]. Prior to 
treatment, cells were synchronized in the cell cycle by 
serum starvation for 24 h. After treatment, the cells were 
fixed in 80% ice cold ethanol, and incubated with 0.5% 
Triton X-100 solution containing 1  mg/ml RNase A at 
37  °C for 30 min. PI was added to a final concentration 
of 50  μg/ml followed by 30  min incubation in the dark. 
Cellular DNA content was analyzed by a fluorescence-
activated cell sorter (FACS; Becton–Dickinson, NJ, USA). 
Data were processed by ModFit LT software (Verity Soft-
ware House, ME, USA).
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Real‑time PCR
Total RNA was extracted using Trizol reagent (Invitrogen, 
CA, USA) according to the manufacturer’s protocol. After 
spectrophotometric quantification, 1  μg total RNA in a 
final volume of 20 μl was used for reverse transcription 
with PrimeScript RT Reagent Kit (TaKaRa, Otsu, Shiga, 
Japan) according to the manufacturer’s protocol. Aliquots 
of cDNA corresponding to equal amounts of RNA were 
used for quantification of mRNA by real-time PCR using 
the LightCycler 96 Real-time Quantitative PCR Detec-
tion System (Roche, Indianapolis, IN, USA). The reaction 
system (25  μl) contained the corresponding cDNA, for-
ward and reverse primers, and SYBR Green PCR master 
mix (Roche). All data were analyzed using β-actin gene 
expression as an internal standard. The specific primers 
were as follows: (1) Cyclin D1, forward, 5′-GCATCTACA 
CCGACAACTCCAT-3′, reverse, 5′-GTTTGTTCTCCTCC 
GCCTCT-3′, product, 153  bp; (2) Cyclin D2, forward, 
5′-CTGAATACTCCTCCCCTCTTCTCTT-3′, reverse, 
5′-TCAGCAGGAAGGGGTGTCTCT-3′, product, 
142 bp; (3) Cyclin D3, forward, 5′-CAGCCAGACCAGCA 
CTCCTAC-3′, reverse, 5′-GAAGGGGGAACAGACGC 
C-3′, product, 162 bp; (4) Cyclin E, forward, 5′-AAGGTT 
TCAGGGTATCAGTGGTG-3′, reverse, 5′-TGCTCGGG 
CTTTGTCCAG-3′, product, 183  bp; (5) CDK2, forward, 
5′-AATAGGCTGGGAGACTGAAGACT-3′, reverse, 5′-AT 
CCTTGGCAACTGAACAACTAA-3′, product, 228 bp; (6) 
CDK4, forward, 5′-TGGAGTGTTGGCTGTATCTTTG 
CT-3′, reverse, 5′-GCAGCCCAATCAGGTCAAAG-3′, 
product, 106 bp; (7) CDK6, forward, 5′-CCCTGTCTCA 
CCCATACTTCC-3′, reverse, 5′-GCCTCCAGATAGCA 
ATCCTCC-3′, product, 204  bp; (8) β-actin, forward, 
5′-TCATGAAGTGTGACGTGGACAT-3′, reverse, 5′-CT 
CAGGAGGAGCAATGATCTTG-3′, product, 158 bp.
Immunofluorescence
Cells were 4% formaldehyde fixed (10  min) at 0.5  h 
post 40  Gy Cs137-irradiation and then incubated with 
1% BSA and 0.3% triton for 1  h to permeabilise the 
cells and block non-specific protein–protein interac-
tions. The cells were then incubated with the Phospho-
Histone H2A.X (Ser139) (20E3) Rabbit antibody (Cell 
Signaling Technology, Beverly, MA, USA) (1:400) over-
night at 4 °C. The secendary antibody was Alexa Fluor® 
488 Conjugated anti-rabbit (Cell Signaling Technol-
ogy, Beverly, MA, USA) IgG (H+L) used at a 1:2000 
dilution for 1 h. DAPI was used to stain the cell nuclei 
(blue). Fluorescence signals were taken with Leica fluo-
rescence microscope DM4000 (Leica Wetzlar GmbH, 
Germany).
Luciferase reporter gene assay
The reporter plasmid, pNF-κB-luc, containing the 
κB-enhancer consensus sequences [(TGGGGACTTTC-
CGC)  ×5] and NF-κB-dependent firefly luciferase gene 
[18] was purchased from Stratagene (La Jolla, CA, USA). 
The internal control plasmid, pRL-SV40, which contains 
the renilla luciferase gene, was obtained from Promega 
(Madison, WI, USA). Cells were transiently cotransfected 
with the reporter plasmid (500  ng/well) and the pRL-
SV40 plasmid (100 ng/well) for 8 h using Lipofectamine 
3000 according to the protocol of the manufacturer. The 
medium was then renewed and treatments were started. 
After treatment, the cell lysates were subjected to the 
dual luciferase reporter assay (Promega) according to 
the recommendations of the manufacturer and lucif-
erase activities were measured with the GloMax-20/20 
luminometer (Promega). The results were expressed 
as relative luciferase activity, which is the ratio of firefly 
luciferase activity to renilla luciferase activity.
Apoptosis assays
Apoptosis was evaluated using the Annexin V-FITC/PI 
Apoptosis Detection kit (Biouniquer Technology, Nan-
jing, China) according to the manufacturer’s instruc-
tions [14]. The cells were resuspended in binding buffer, 
and Annexin V-FITC and propidium iodide (PI) were 
added to the buffer and incubated at room temperature 
for 15 min in the dark, followed by flow cytometry using 
a Beckman Coulter FC500 dual-laser five-color flow 
cytometer (Beckman Coulter, Fullerton, CA, USA).
Western blot analysis
Total protein was extracted using a lysis buffer containing 
50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 
0.1% sodium dodecyl sulfate (SDS), 1  mM EDTA, protease 
inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mg/ml 
pepstatin A, 1 mM 4-[2-aminoethyl] benzenesulfonyl fluoride), 
and phosphatase inhibitors (1 mM NaF, 1 mM Na3VO4). The 
protein extracts were separated by 10% SDS–polyacrylamide 
gel electrophoresis (PAGE) and were transferred to polyvi-
nylidene fluoride (PVDF) membranes (Millipore, St Charles, 
MO, USA). After 1-h blocking in 5% non-fat milk, the mem-
branes were incubated overnight with primary antibodies, 
rabbit anti-RIP3 (Cell Signaling Technology) or mouse anti-β-
actin (Santa Cruz Biotechnologies, CA, USA), at 4 °C. Protein 
expression was determined using horseradish peroxidase—
conjugated antibodies followed by enhanced chemilumines-
cence) (ECL) detection (Millipore). Protein band analysis was 
performed using Quantity One 4.6.2 software (Bio-Rad Labo-
ratories, CA, USA). β-actin was used as internal control.
Page 4 of 12Wu et al. Cancer Cell Int  (2017) 17:13 
Transfection of small interfering RNA
Target specific small interfering RNAs (siRNAs) were 
synthesized by Genepharma (Shanghai, China). The 
specific sequences were as follows: (1) Control-siRNA, 
5′-UUCUCCGAACGUGUCACGUdTdT-3′; (2) RIP3- 
siRNA-1, 5′-UAACUUGACGCACGACAUCAGGCUGU 
U-3′; (3) RIP3-siRNA-2, 5′-GCAGUUGUAUAUGUUAAC 
GAGCGGUCG-3′ [19]. The transfections were per-
formed with siRNA-Mate Transfection Reagent (Genep-
harma) according to the manufacturer’s protocol.
Statistical analysis
Each experiment was performed a minimum of three 
times. Results were expressed as the mean value ± stand-
ard deviation (SD). Statistical analysis was performed by 
unpaired Student’s t test. A P value <0.05 was considered 
significant.
Results
The chemotherapy sensitization effect of TNF‑α 
against breast cancer cells and xenografts
The growth inhibition effects of chemotherapeutics, 
docetaxel, 5-FU and cisplatin, against breast cancer cells 
were firstly evaluated by using MTT assays. As shown in 
Fig. 1a–c, docetaxel, 5-FU and cisplatin repressed growth 
of MDA-MB-231 and MCF-7 cells through dose- and 
time-dependent manner. The IC50 values, 48 and 72  h 
post treatment with each chemotherapeutic, were pre-
sented in Table 1.
According to IC50 values of chemotherapeutics, chem-
otherapy sensitization effect of TNF-α was evaluated 
in  vitro. Co-treatment with TNF-α strengthened the 
growth inhibition induced by docetaxel, 5-FU and cispl-
atin remarkably (Fig. 1d–f). The chemotherapy sensitiza-
tion effect was then assessed in vivo. As shown in Fig. 1g, 
h, TNF-α strengthened the suppression on the forma-
tion of xenografts by chemotherapeutics, confirming 
that TNF-α preserved synergetic effect on breast cancer 
growth with chemotherapeutics.
The radiotherapy sensitization effect of TNF‑α 
against breast cancer cells
To verify the radiotherapy sensitization effect of TNF-
α, we measured the dynamic formation of phosphoryl-
ated H2A.X (γ-H2A.X), a marker of DNA double-strand 
breaks (DSBs) [20–22], in breast cancer cells after a dose 
of 40 Gy Cs137-irradiation. As shown in Fig. 2, the num-
ber of γ-H2A.X foci increased 30  min post irradiation. 
TNF-α treatment up-regulated γ-H2A.X foci formation 
to higher levels, suggesting the co-treatment of TNF-α 
brought more DNA damages.
TNF‑α upregulated cyclin D1, Cyclin D2, Cyclin E, 
CDK4 and CDK6 through activating NF‑κB pathway, 
and accelerated G1→S cell cycle transition
Cancer cells in G0/G1 cell cycle have been proved to 
be quiescent and resistant to chemotherapy and radi-
otherapy. Since TNF-α sensitized chemotherapy and 
radiotherapy, we then performed cell cycle analysis 
to explore the effect of TNF-α on cell cycle distribu-
tion. As shown in Fig. 3a and b, treatment with TNF-α 
induced remarkable decreased G0/G1 phase popula-
tion and increased S plus G2/M phase proportion. 
These results indicated that TNF-α could drive cells out 
of quiescent G0/G1 phase, entering chemotherapy- and 
radiotherapy-sensitive proliferating phases.
Cyclin D1, Cyclin D2, Cyclin D3, Cyclin E, CDK2, 
CDK4 and CDK6 are the key regulators participat-
ing in G1→S phase transition, and NF-κB is the main 
pathway at the downstream of TNF-α stimulation. 
Therefore, we then investigate whether TNF-α could 
regulate expressions of G1→S phase transition regu-
lators through NF-κB pathway dependent manner. 
Activation of NF-κB pathway was firstly confirmed by 
luciferase report gene assays (Fig.  3c). Treatment of 
TNF-α up-regulated Cyclin D1 and Cyclin D2 in MDA-
MB-231 cells, and increased expressions of Cyclin E, 
CDK4 and CDK6 in MCF-7 cells (Fig. 3d–j). Pre-treat-
ment of Bay11-7082, an inhibitor of NF-κB pathway, 
(See figure on next page.) 
Fig. 1 TNF‑α sensitized cytotoxicity of docetaxel (DOC), 5‑flurouracil (5‑FU) and cisplatin (DDP) against MDA‑MB‑231 and MCF‑7 breast cancer cells. 
a–c Dose‑ and time‑dependent cytotoxicity of docetaxel (DOC) (a), 5‑flurouracil (5‑FU) (b) and cisplatin (DDP) (c). **P < 0.01 indicated significant 
differences from the respective control groups. d–f Enhanced cytotoxicity of docetaxel (DOC) (d), 5‑flurouracil (5‑FU) (e) and cisplatin (DDP) (f) with 
combined treatment of TNF‑α (5 ng/ml). *P < 0.05 and **P < 0.01 indicated significant differences from the respective control groups; #P < 0.05 
and ##P < 0.01 indicated significant differences from the TNF‑α (5 ng/ml) treated groups; &&P < 0.01 indicated significant differences between 
folds induction. g, h TNF‑α (20 ng each injection, intratumorally, every 3 days) strengthened growth inhibition effect of docetaxel (DOC, 2 mg/kg, 
intravenously, every 3 days), 5‑flurouracil (5‑FU, 10 mg/kg, intraperitoneally, everyday) and cisplatin (DDP, 2 mg/kg, intraperitoneally, every 3 days) 
against breast cancer xenografts in vivo. g Image of stripped xenografts. h Tumor weight of each group. **P < 0.01 indicated significant differences 
from control group; ##P < 0.01 indicated significant differences from TNF‑α treated group; &&P < 0.01 indicated significant differences between folds 
induction
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attenuated the up-regulation of Cyclin D1, Cyclin 
D2, Cyclin E, CDK4 and CDK6 (Fig.  3d–j), suggest-
ing TNF-α up-regulated key regulators participating 
in G1→S cell cycle transition through NF-κB pathway 
dependent manner.
TNF‑α strengthened cell cycle arrest induced by docetaxel 
and cisplatin
We then investigated whether the chemotherapy sensi-
tization effect could involve the regulation on cell cycle 
distribution. As shown in Fig.  4a, docetaxel induced 
G2/M cell arrest and decreased population of cells at 
G0/G1 plus S phases, consisting with its microtubule 
structure stability role [23]. Co-treatment with TNF-α 
increased G2/M cell cycle arrest which was induced by 
docetaxel.
Cisplatin induced accumulation of cells at S phase in 
Fig. 4b, due to its DNA crosslinking role [24]. Co-treat-
ment with TNF-α increased S phase cell cycle arrest 
induced by cisplatin.
Therefore, TNF-α drove cells out of G0/G1 phase, lead-
ing more cells entering S and G2/M phase and these pro-
portions were further arrested by cisplatin and docetaxel 
at S and G2/M phases respectively.
TNF‑α increased necroptosis induced by 5‑FU
Figure  5a revealed that 5-FU caused G0/G1 cell arrest 
through its inhibition of thymidylate synthase [25]. 
Therefore, TNF-α might not be able to drove cells out of 
G0/G1 phase in this circumstance. However, combined 
application of TNF-α with 5-FU induced a significant 
sub G0/G1 peak, suggesting necrosis and/or apoptosis 
induction might be involved in the TNF-α-induced 5-FU 
sensitization.
Therefore, we performed apoptosis assays to further 
investigate the mechanisms involved. The percentages of 
cell populations at various stages of apoptosis are shown 
in Fig. 5b. After co-treatment with TNF-α and 5-FU, the 
numbers of cells that underwent later apoptosis and/
or necrosis (Annexin V+/PI+) increased significantly. 
These data suggested that the enhanced growth-inhi-
bition effect of TNF-α combined with antitumor drugs 
Table 1 The IC50 values of docetaxel (DOC), 5-Fluorouracil 
(5-FU) or cisplatin (DDP) in MDA-MB-231 and MCF7 cells
MDA‑MB‑231 MCF7
48 h 72 h 48 h 72 h
DOC (μM) 75.35 45.45 83.64 47.74
5‑FU 119.33 mM 89.22 μM 5.75 mM 31.98 μM
DDP (μM) 13.48 8.61 59.71 47.39
Fig. 2 The radiotherapy sensitization effect of TNF‑α. Formation of phosphorylated H2A.X (γ‑H2A.X), a marker for DNA damage, was visualized in 
MDA‑MB‑231 (a) and MCF‑7 (b) cells 30 min after a dose of 40 Gy Cs137‑irradiation
Page 7 of 12Wu et al. Cancer Cell Int  (2017) 17:13 
could be due to induction of later apoptosis and/or 
necrosis.
It has been reported that necrosis induced by TNF-α 
is distinguished from traditional necrosis, and termed as 
necroptosis (programmed necrosis) [26]. Therefore, we 
evaluated the activation of necroptosis marker, recep-
tor-interacting protein kinase 3 (RIP3), by using West-
ern blot. As shown in Fig. 5c, TNF-α treatment induced 
phosphorylation, the active form of RIP3 [26]. 5-FU had 
no effect on RIP3 phosphorylation, but up-regulated 
expression of RIP3. Therefore, co-treatment of TNF-α 
and 5-FU led to significant activation of RIP3, suggesting 
the involvement of necroptosis in the 5-FU sensitization 
effect of TNF-α.
To verify whether the chemotherapy sensitization 
effect of TNF-α on 5-FU was executed through a RIP3-
dependent manner, we applied siRNAs targeting RIP3 
(Fig. 5d). As expected, knockdown of RIP3 attenuated the 
synergetic effect of TNF-α and 5-FU (Fig. 5e), indicating 
TNF-α strengthened cytotoxicity of 5-FU through RIP3-
dependent necroptosis.
Discussion
Resistance to anticancer drugs and radiotherapy is the 
primary reason for treatment failure in cancer [27]. Cyto-
toxic agents and radiotherapy killed only proliferating 
cancer cells and, in contrast, had little effect on quies-
cent cancer cells [28]. After cessation of chemotherapy 
and radiotherapy, these therapeutic-resistant quiescent 
cancer cells restarted cycling, leading to a relapse situa-
tion.  Therefore, drugs that target quiescent cancer cells 
are urgently needed. In our present study, we proved that, 
TNF-α preserved the radiotherapy-sensitizing ability and 
strengthened cytotoxicity of chemotherapeutics, includ-
ing docetaxel, cisplatin and 5-FU, making TNF-α a prom-
ising candidate for further clinical application.
Mitotic cellular division requires the cell to leave the 
resting state and proceed through phases of DNA syn-
thesis and mitosis. Well-organized progression of divid-
ing cells through the G0, G1, S, G2, and M phases of 
the cell cycle in eukaryotic cells relies on a series of cell-
cycle regulatory proteins, such as Cyclin A, B, D and E, 
and these cyclins exert their functions via binding to and 
activating a variety of specific cyclin-dependent kinases 
(CDKs) [29]. Furthermore, there are a number of kinases 
and phosphatases which modulate CDK respectively 
through a way of phosphorylation and dephosphoryla-
tion. For instance, the regulation of the CDKs activ-
ity is associated with many CDK inhibitors (CKIs), and 
cell cycle checkpoint proteins. Cell division is conceived 
as a passage through these checkpoints. The earliest of 
these is the ‘‘restriction point’’ late in G1, when the cell 
becomes irreversibly transformed to DNA synthesis and 
mitosis. Cyclin D1 is a key regulator of G1/S checkpoint 
control, which forms a holoenzyme complex with CDK4 
and CDK6, to phosphorylate pRb (retinoblastoma pro-
tein) [30]. When phosphorylated, pRB releases transcrip-
tion facctor E2F to promote cell cycle [29, 31]. Previous 
studies have shown that the Cyclin D1 promoter region 
includes binding sites for NF-κB [32], and NF-κB is 
required to induce Cyclin D1 expression and pRb hyper-
phosphorylation to promote G1→S transition. There are 
other two D group of cyclins, Cyclin D2 and Cyclin D3. 
Cyclin D2 abundance peaks in late G1-phase. And cyc-
lin D3 peaks during S-phase. Like cyclin D1, both Cyclin 
D2 and Cyclin D3 associate with CDK4 and CDK6, form-
ing holoenzyme complexes that phosphorylate pRB [33]. 
Cyclin E, which forms a complex with CDK2, reaches 
abundance peak in late G1-phase [34]. The Cyclin E/
CDK2 complex also phosphorylates pRB, although some 
phosphorylation sites are distinct from those targeted 
by kinases associating with D group cyclins. Consistent 
with our results in Fig.  3, apparently, the activation of 
NF-κB by the pre-treatment of TNF-α stimulates tran-
scriptions of Cyclin D1, Cyclin D2, Cyclin E, CDK4 and 
CDK6 to accelerate the progression of cell cycle from G0/
G1 phase to S phase. As a result, TNF-α drove quiescent 
cancer cells out of G0/G1 phase, entering treatment sen-
sitive proliferating phases. By using cell cycle analysis, we 
further confirmed that TNF-α strengthened the G2/M 
phase and S phase cell cycle arresting ability of docetaxel 
and cisplatin respectively.
Actually, TNF-α is a pleiotropic cytokine that plays a 
vital role in a wide variety of physiological processes [35]. 
The pleiotropic nature of TNF-α response results from 
the sequential formation of different signaling complexes 
via binding of TNF-α to its receptor. So far, there are two 
identified TNF-α receptors, TNF-α receptor 1 (TNFR1) 
and TNF-α receptor 2 (TNFR2), both of which belong to 
the TNFR superfamily. TNFR1 has a single intracellular 
death domain (DD), whereas TNFR2 has a TNF recep-
tor-associated factor (TRAF)-binding area [36]. There is 
a broad body of evidences that TNF-induced cell death 
is largely mediated via TNFR1 [6, 8, 10, 23]. Binding to 
TNFR1 can cause apoptosis by caspase 8 or necropto-
sis by receptor-interacting protein kinase 1 (RIP1)- and 
RIP3-dependent mechanisms [36–38]. Necroptosis, or 
programmed necrosis, refers to a caspase-8-independ-
ent death mechanism triggered by RIP1 and RIP3. RIP1 
bears a DD that can interact with TNFR1, upon binding 
of TNF-α, RIP1 is recruited to TNFR1 either directly via 
its DD or indirectly by TRADD, to form a complex on 
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the cytoplasmic domain of TNFR1 [39]. The complex is 
released from TNFR1 and RIP3 to cause necroptosis. If 
cells have high level of RIP3, RIP1 recruits RIP3 to form 
necrosome containing FADD [40, 41],  caspase-8, RIP1, 
and RIP3, and the cells undergo necroptosis. Necrosome 
also suppresses apoptosis but the underlying mecha-
nism has not been described yet. Mixed-lineage kinase 
domain-like (MLKL) is downstream of RIP3 [42, 43], 
the phosphorylated RIP3 recruits MLKL, and phospho-
rylation of MLKL is required for subsequent execution 
of necroptosis. Therefore, RIP3 is conceived as a key reg-
ulator of necroptosis.
5-FU can suppress thymidylate synthase and block 
DNA synthesis, causing a restraint of the transition 
from G1 phase to S phase [25]. Although the G0/G1 cell 
cycle arrest effect of 5-FU may antagonise the G1→S 
transition accelerating effect of TNF-α, co-treatment 
with TNF-α still strengthened the cytotoxicity of 5-FU, 
suggesting mechanisms beyond cell cycle regulation 
might be involved. It was noteworthy that there was a 
significant peak in sub G0/G1 phase in the co-treating 
group. Therefore, we carried out the apoptosis assays 
and detected a remarkble Annexin V+/PI+  population 
in the combination group of TNF-α and 5-FU, suggest-
ing an apoptosis and/or necroptosis mechanism might be 
involved. We further demonstrated that 5-FU was able to 
up-regulate RIP3 expression. Since TNF-α activates RIP3 
and induce necroptosis, the synergistic effect of co-treat-
ment of TNF-α and 5-FU might be executed through 
elevated necroptosis. In consisting with this assumption, 
RIP3 siRNA apparently attenuated the synergistic effect 
by the combination of TNF-α and 5-FU.
In conclusion, we presently proved that, TNF-α present 
radiotherapy- and chemotherapy-sensitizing effect against 
breast cancer cells. TNF-α drove cells out of quiescent 
G0/G1 phase, entering vulnerable proliferating phases. As 
Fig. 4 TNF‑α strengthened cell cycle arrest induced by docetaxel (DOC) and cisplatin (DDP) in MDA‑MB‑231 breast cancer cells. a Cell cycle distri‑
bution after treatment with TNF‑α (5 ng/ml) and/or docetaxel (20 μM). b Cell cycle distribution after treatment with TNF‑α (5 ng/ml) and/or cisplatin 
(10 μM)
(See figure on previous page.) 
Fig. 3 TNF‑α promoted G1→S cell cycle transition through NF‑κB pathway dependent manner. a, b Effects of TNF‑α (5 ng/ml) on cell cycle distri‑
bution in MDA‑MB‑231 (a) and MCF‑7 (b) cells 24 h post treatment. c Relative luciferase activity of NF‑κB after treatment with TNF‑α (5 ng/ml) for 
24 h. **P < 0.01 indicates significant differences from the respective control groups. d–j Expressions of Cyclin D1 (d), CDK4 (e), CDK6 (f), Cyclin D2 
(g), Cyclin D3 (h), Cyclin E (i), and CDK2 (j) after treatment of TNF‑α (5 ng/ml) and/or NF‑κB inhibitor, Bay11‑7082 (Bay, 20 μM). **P < 0.01 indicates 
significant differences from the respective control groups; ##P < 0.01 indicated significant differences from the TNF‑α (5 ng/ml) treated groups; 
&&P < 0.01 indicated significant differences between folds induction
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Fig. 5 Co‑treatment of TNF‑α and 5‑FU induced necroptosis in MDA‑MB‑231 breast cancer cells. a Cell cycle distribution after treatment with TNF‑α 
(5 ng/ml) and/or 5‑FU (12 μM). b Apoptosis/necrosis rate after treatment with TNF‑α and/or 5‑FU. c Protein level of necroptosis marker, RIP3, after 
treatment with TNF‑α and/or 5‑FU. d Confirmation of knockdown of RIP3 by using real‑time PCR. e Effect of RIP3 knockdown on the synergetic 
effect of TNF‑α and 5‑FU. **P < 0.01 indicated significant differences from the respective control groups; ##P < 0.01 indicated significant differences 
from the TNF‑α (5 ng/ml) treated groups; &P < 0.05, &&P < 0.01 and @@P < 0.01 indicated significant differences between folds induction
a result, TNF-α brought more DNA damage after irradia-
tion and strengthened G2/M and S phase cell cycle arrest 
induced by docetaxel and cisplatin respectively. Moreo-
ver, the up-regulation of RIP3 by 5-FU, and the activation 
of RIP3 by TNF-α, synergistically triggered necroptosis. 
Taking together, our present investigation brought new 
strategies for breast cancer treatment through sensitized 
chemotherapy and radiotherapy by TNF-α.
Conclusions
TNF-α presented radiotherapy- and chemotherapy-sen-
sitizing effects against breast cancer cells.
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